Cod liver oil inhibits indomethacin induced gastropathy without affecting its bioavailability and pharmacological activity.
The upper gastrointestinal toxicity is one of the most common side effects associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Many attempts to prepare potent NSAIDs free from gastrotoxicity have failed. Hence, development of formulations to mask the gastropathy of NSAIDs are warranted. The present study was undertaken to investigate the effect of concomitant use of cod liver oil (CLO) on pharmacological activity and gastropathy of indomethacin in rats. The animals were treated with CLO (5 and 10 ml/kg body weight) along with indomethacin (30 mg/kg, body weight). Blood samples were collected for analysis of indomethacin at 0.25, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0 and 24 hours. The anti-inflammatory activity of indomethacin alone and in combination with CLO was studied using carrageenan-induced paw oedema. Our studies related to the effect of these drugs on gastrointestinal tract showed that concurrent use of CLO protects gastric mucosa against indomethacin induced depletion of gastric wall mucus, non protein sulfhydryl (NP-SH) levels and gastric lesions. The result of this study also showed that the concurrent use of the CLO does not affect the bioavailability and anti-inflammatory activity of indomethacin while it inhibits the ulcerogenic effect of indomethacin in a dose dependent manner. These findings suggest that NSAIDs formulations containing CLO may reduce gastrotoxicity without affecting their therapeutic efficacy.